[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-markers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-markers":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100612503","phase-2-compass---copenhagen-menopause-study-100612503",false,"NCT07254429","COMPASS - COpenhagen MenoPAuSe Study","Copenhagen Menopause Study (COMPASS): A Randomized Clinical Trial","COMPASS","Inclusion Criteria:\n\n* Women \\>40 years and ≤65 at screening visit\n* A body mass index between 18-35\n* Confirmed menopause\n\n  * Method 1\n  * Spontaneous amenorrhea for ≥12 consecutive months\n  * Negative urine hCG test\n  * Method 2\n  * Spontaneous amenorrhea for ≥6 months\n  * FSH \\>30 mIU\u002FL\n  * Negative urine hCG test\n* Moderate to severe vasomotor symptoms (VMS)\n\n  * Within the 7 days prior to randomization, participants must report ≥ 14 moderate to severe VMS per week\n\nExclusion Criteria:\n\n* Current or previous hormone replacement therapy (HRT)\n\n  * Vaginal estradiol\u002Fvaginal inserts (e.g. Vagifem®) can be used, but will have to be pause 2 weeks prior to randomization and throughout the study period\n  * Menopausal Hormone Therapy (MHT) can be used by participants, but must be paused 6 weeks prior to inclusion.\n* Current or previous cancer diagnosis\n\n  * Except for basal cell carcinoma\n* Known BRCA gene mutation\n* Current hyperthyroid disease\n* Osteoporosis\n* Major psychiatric diagnosis including ongoing medication e.g. selective serotonin re-uptake inhibitors (SSRIs)\n* Known prolonged QT or other known clinically significant abnormal ECG, including taking medication that can prolong QT interval (e.g. sotalol, dronedarone, amiodarone, methadone, and several antipsychotic drugs)\n* Previous myocardial infarction or heart failure\n* Previous thromboembolic event\n* The use of opioids, anticoagulating treatment or unwilling to pause fish oil\u002FOmega-3 supplements 3 days prior visit 1 and 3\n* Current alcohol or drug abuse\n* Hypertension treated with more than two drugs\n* Severe history of allergy, hypersensitivity, or intolerance to drugs\n* Moderate to severe liver and kidney disease (eGFR \\\u003C60 mL\u002Fmin)\n* Diagnosed with type 1 or 2 diabetes\n* Chronic diseases requiring immunomodulatory treatments such as rheumatoid arthritis, inflammatory bowel disease, and vasculitis etc.\n* Known uterine fibroids, Endometriosis, Systemic lupus erythematosus (SLE), otosclerosis, severe migraine or sleep apnea\n* Known Epilepsy or previous seizures or convulsive disorder","FEMALE","40 Years","65 Years",{"count":21,"type":22},192,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms and complications of menopause since it is known from previous research that high LH levels contribute to both bone deterioration and metabolic issues. The goal is to explore new treatment options that can improve health and quality of life for women both during and after menopause. This randomized clinical trial is a single center, sponsor-investigator-initiated single-blinded 8 weeks clinical trial with four parallel groups comparing the effect of an gonadotropin releasing hormone(GnRH)-analog with placebo, and with two additional arms given estrogen or testosterone on change on bone health in postmenopausal women with moderate-to-severe symptoms.",[28,29],"Menopausal Osteoporosis","Bone Markers","RECRUITING","2026-02-27",{"date":33,"type":34},"2026-03-02","ACTUAL",{"date":36,"type":34},"2025-10-02",{"date":38,"type":22},"2028-05",{"name":40,"class":41},"Martin Blomberg Jensen","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100607784","the-cph-mbd-cohort-100607784","NCT07193056","The CPH-MBD Cohort","Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort","Inclusion Criteria:\n\n* Age ≥18 years\n* CKD stage 4-5nonD (eGFR ≤ 29 ml\u002Fmin) according to KDIGO (Kidney Disease Improving Global Outcome) definition\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":53,"type":22},1000,"25 Years","OBSERVATIONAL","Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population. These increased risks are related to the disturbances in the mineral metabolism, and this clinical entity is termed Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD).\n\nThe overall aim of the present project is to explore factors that may predict or associate with the development of bone and cardiovascular disease in patients with CKD and hopefully provide insight into underlying mechanisms and pathophysiological pathways for future treatment and prevention.\n\nIn a sub study investigators aim to explore the calcium and phosphate balance in patients with CKD and describe how these associate with each other as well as with kidney function (eGFR).",[58,59,29],"Chronic Kidney Disease Mineral and Bone Disorder","Chronic Kidney Disease (CKD)",[61,62,63,64,65],"bone markers","parathyroid hormone","fracture risk","bone turnover","dietary assessment","NOT_YET_RECRUITING","2025-12-24",{"date":69,"type":34},"2025-12-31",{"date":71,"type":22},"2025-12",{"date":73,"type":22},"2055-01",{"name":75,"class":41},"Herlev Hospital"]